Phase I/II clinical trials of tecotabart vedotin plus immune checkpoint inhibitor toripalimab (NCT05188664 and NCT05934331) revealed ORR of 73% (24/33) in G/GEJAC or esophageal adenocarcinoma patients with CLDN18.2 staining of 2+/3+ intensity in at least 25% of tumor cells (Jiang et al., 2025). The gene discussed is CLDN18; the disease is neoplasm.